A pre-visit infographic plus brief smartphone messages over five days boosted albuminuria testing among 57 adults with hypertension: EHR-confirmed urine testing reached 36.8% versus 11.0% in 182 contemporaneous controls (risk ratio 3.35; 2.93 after propensity matching). Knowledge that hypertensive adults need urine testing rose from 58% to 95%, and 77% of participants asked their clinician about testing.
Urine albumin screening is cheap and noninvasive, yet most hypertensive adults never get it, so kidney damage goes undetected until late. Early detection matters because it can change treatment: blood-pressure targets, ACE inhibitors or ARBs, and newer kidney-protective drugs. A patient-activation approach is appealing because it sidesteps the clinician-side alert fatigue that undermines many EHR prompts. Even so, caution is warranted. This is a preprint that has not been peer-reviewed, the design is non-randomized, and participants who opted into a program likely differed from controls in motivation, so propensity matching cannot fully close that gap. Sixty-five percent self-reported that testing was ordered, yet only 37% had EHR-confirmed results, so even the engaged group fell well short of universal screening. The study also measures testing, not downstream detection, treatment changes, or kidney outcomes. It comes from a single academic center with a small sample. Overall, it is an incremental, hypothesis-generating proof of concept. In practice, adults with hypertension can ask their clinician about a urine albumin-to-creatinine ratio, which is a low-effort step the findings support, though a randomized trial in routine care is needed.